Viridian Therapeutics stock popped Monday after the biotech company scored a win in thyroid eye disease, a condition that causes the eyes to swell. Please watch the video at Investors.com - How To ...

Viridian announced that in a late-stage trial, 56% of veligrotug-treated patients experienced a reduction in proptosis, or abnormal eye bulging, achieving a mean reduction of 2.34 mm. Additionally ...

Viridian is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The company is conducting a pivotal program for veligrotug (VRDN-001 ...